Table 1. The estimated prevalence and penetrance of AIP.
| Country (region) or Population | Prevalence of symptomatic AIP (case per million inhabitants) | Prevalence of pathogenetic HMBS mutations | Penetrance (%) | Ref. | ||
|---|---|---|---|---|---|---|
| Caucasian | 1/1,782 | < 1 | 14 | |||
| Europe | 5.9 | 19 | ||||
| France | 7.6 | 1/1,299 | 0.5-1 | 22.9 | 25 | |
| 1/1,675 | 15 | |||||
| 5.5 | 19 | |||||
| Sweden | 23 | 23 | 19 | |||
| 1/10,000 | 30 | |||||
| Northern Sweden | 1/1,000 | 30 | ||||
| 192 | 1/2,000 | 42 | 27 | |||
| Switzerland | 10-15 | 50 | 52 | 31 | ||
| 9.9 | 19 | |||||
| Southeastern Spain | 17.7 | 26 | ||||
| Spain | 6.3 | 52 | 19 | |||
| Finland | 47 | 35 | 32 | |||
| 5.9 | 19 | |||||
| Norway | 6.3 | 19 | ||||
| Northern Italy | 5.0 | 19 | ||||
| Poland | 7.2 | 19 | ||||
| UK | 7.2 | 19 | ||||
| Netherlands | 8.1 | 19 | ||||
| Russia | 59 | 57 | 58 | |||
| Argentina* | 8 | 40 | 28 | |||
| Western Australia* | 24 | 29 | 29 | |||
*No gene sequencing was performed in the study